During weight loss interventions, medical management was initiated in 12/30 women (progesterone-containing intrauterine or an aromatase inhibitor) with either grade 1 endometrioid carcinoma or atypical endometrial hyperplasia. The gene discussed is CYP19A1; the disease is atypical endometrial hyperplasia.